Volume 7, Issue 6, December 2019, Page: 95-99
Human Papillomavirus Types and Cervical Cancer Vaccine for Sudanese Women: A Review
Magdi Mansour Salih, Department of Clinical Laboratory Sciences, Taif University, Taif, Kingdom of Saudi Arabia
Received: Sep. 30, 2019;       Accepted: Oct. 28, 2019;       Published: Oct. 31, 2019
DOI: 10.11648/j.ejpm.20190706.11      View  63      Downloads  13
Abstract
Cervical cancer is thought to result from different high-risk human papillomavirus (HPV) types. Although many studies have been conducted worldwide regarding HPV infection and its oncogenic properties, limited data are available on the incidence and genotype specific dissemination of HPV in Sudan. The purpose of this review article is to summarize the existing data regarding HPV genotypes in Sudan. To review the distribution of HPV infections, electronic databases (e.g. PubMed, and Google Scholar) were searched for peer reviewed articles in English. The study was performed between January and April of 2019 and comprises a review of six relevant articles that were published prior to 2013. Inclusion criteria included: availability of general population data, cytology and tissue results and the use of polymerase chain reaction (PCR) for HPV detection. The overall infection rate of high-risk HPVs DNA was 173/506 (34%) and within the tissues ranged between 93 and 94% (all the paraffin sections were cancer and precancerous cases). The HPV genotyping in cervical smears were found to range from 2.9% to 50.0%, with the most prevalent types of HPV being 16 (2.9-50.0%), 18 (0-3.4%), 58 (2.9%), and 42 (2.9%). Familiarity of the frequent high risk HPV genotypes found in Sudan, which had a high prevalence of cervical cancer, is essential in order to construct an applicable genotype of the virus in the HPV vaccine. The commercially available vaccines do not prevent infection of the HPV types not contained in the vaccine. Based on this literature, it is clear that the nine-valent HPV vaccine should be considered in Sudan.
Keywords
Human Papilloma Virus Genotypes Vaccine, Cervical Cancer
To cite this article
Magdi Mansour Salih, Human Papillomavirus Types and Cervical Cancer Vaccine for Sudanese Women: A Review, European Journal of Preventive Medicine. Vol. 7, No. 6, 2019, pp. 95-99. doi: 10.11648/j.ejpm.20190706.11
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Ibrahim, A. et al. (2012) ‘Cervical cancer screening in primary health care setting in Sudan: A comparative study of visual inspection with acetic acid and Pap smear’, International Journal of Women’s Health. 4: 67-73 doi: 10.2147/IJWH.S28406.
[2]
McLaughlin-Drubin, M. E. and Munger, K. (2008) ‘Viruses associated with human cancer’, Biochimica et Biophysica Acta - Molecular Basis of Disease. doi: 10.1016/j.bbadis.2007.12.005.
[3]
Denny, L. A. et al. (2012) ‘Human papillomavirus, human immunodeficiency virus and immunosuppression’, Vaccine. doi: 10.1016/j.vaccine.2012.06.045.
[4]
Institut Català d’Oncologia (ICO) (2016) ‘Human Papillomavirus and Related Diseases Report’, HPV Information Centre, (October).
[5]
Bernard, H. U. et al. (2010) ‘Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments’, Virology. doi: 10.1016/j.virol.2010.02.002.
[6]
IARC (2007) ‘Human Papillomaviruses: Summary of Data Reported and Evaluation’, Iarc Monographs on the Evaluation of Carcinogenic Risks To Humans, VOLUME 90 (5), pp. 465–477. doi: 10.1016/S1470-2045(05)70086-3.
[7]
Boshartb, M. et al. (1984) ‘A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer’, The EMBO Journal.
[8]
Li, N. et al. (2011) ‘Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication’, International Journal of Cancer. doi: 10.1002/ijc.25396.
[9]
Park, U. et al. (2015) ‘Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines’. Clin Infect Dis. 15; 61 Suppl 8: S 849-55. doi: 10.1093/cid/civ813.
[10]
Frisch, M. et al. (1997) ‘Sexually transmitted infection as a cause of anal cancer.’, The New England journal of medicine, 337 (19), pp. 1350–8. doi: 10.1056/NEJM199711063371904.
[11]
Reiter, P. L., Brewer, N. T. and Smith, J. S. (2010) ‘Human papillomavirus knowledge and vaccine acceptability among a national sample of heterosexual men’, Sexually Transmitted Infections. doi: 10.1136/sti.2009.039065.
[12]
An, H. J. et al. (2003) ‘Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method’, Cancer, 97 (7), pp. 1672–1680. doi: 10.1002/cncr.11235.
[13]
Salih, M. M. et al. (2010) ‘Genotypes of human papilloma virus in Sudanese women with cervical pathology’, Infectious Agents and Cancer. doi: 10.1186/1750-9378-5-26.
[14]
Jacobs, M. V. et al. (1995) ‘Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes’, Journal of Clinical Microbiology, 33 (4), pp. 901–905.
[15]
Moneira, A. M. et al. (2013) Screening for Cervical Cancer and Its Association with Human Papilloma Virus (HPV) among Sudanese Women. Physiology, C. (2013) ‘1,5 1-’, 5 (1), pp. 101–106.
[16]
Elasbali, A. M. et al. (2012) ‘Cervical and Oral Screening for HR-HPV types 16 and 18 among Sudanese Women Cervical Lesions’, Infectious Agents and Cancer. doi: 10.1186/1750-9378-7-17.
[17]
Gafar, S. E. et al. (2013) ‘Screeing for HR-HPV amongest Sudanese Women Visting gynecologic clinic by ISH and PAP. test’, Management in Health. doi: 10.5233/MIH.V17I2.268.
[18]
Abate, E. et al. (2013) ‘Genotyping of human papillomavirus in paraffin embedded cervical tissue samples from women in ethiopia and the Sudan’, Journal of Medical Virology. doi: 10.1002/jmv.23437.
[19]
Eltahir, H. A., Elhassan, A. M. and Ibrahim, M. E. (2012) ‘Contribution of retinoblastoma LOH and the p53 Arg/Pro polymorphism to cervical cancer’, Molecular Medicine Reports, 6 (3), pp. 473–476. doi: 10.3892/mmr.2012.942.
[20]
Zhang, C. et al. (2018) ‘Prevalence of human papillomavirus among Wenzhou women diagnosed with cervical intraepithelial neoplasia and cervical cancer’, Infectious Agents and Cancer. doi: 10.1186/s13027-018-0211-8.
[21]
Walboomers, J. M. M. et al. (1999) ‘Human papillomavirus is a necessary cause of invasive cervical cancer worldwide’, Journal of Pathology. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.
[22]
Bosch, F. X. et al. (2008) ‘Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia’, Vaccine. doi: 10.1016/j.vaccine.2008.05.064.
[23]
Wagner, M. et al. (2015) ‘Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females’, Infectious Agents and Cancer. BioMed Central Ltd., 10 (1). doi: 10.1186/s13027-015-0008-y.
[24]
Hernandez-Suarez, G. et al. (2013) ‘Human papillomavirus genotypes in genital warts in Latin America: A cross-sectional study in Bogota, Colombia’, International Journal of STD and AIDS. doi: 10.1177/0956462412474538.
[25]
Elamin, A. et al. (2015) ‘Part I: Cancer in Sudan-burden, distribution, and trends breast, gynecological, and prostate cancers’, Cancer Medicine. doi: 10.1002/cam4.378.
[26]
Shrestha, A. D. et al. (2018) ‘Cervical Cancer Prevalence, Incidence and Mortality in Low and Middle Income Countries: A Systematic Review’, Asian Pac J Cancer Prev. doi: 10.22034/APJCP.2018.19.2.319.
[27]
Xue, Y. et al. (2017) ‘Cr(III)-induced electrochemical advanced oxidation processes for the V2O3 dissolution in alkaline media’, Chemical Engineering Journal, 307, pp. 518–525. doi: 10.1016/j.cej.2016.08.115.
[28]
Peto, P. J. et al. (2004) ‘The cervical cancer epidemic that screening has prevented in the UK’, Lancet. doi: 10.1016/S0140-6736(04)16674-9.
[29]
Harper, D. M. (2009) ‘Currently approved prophylactic HPV vaccines’, Expert Review of Vaccines, pp. 1663–1679. doi: 10.1586/erv.09.123.
[30]
Giuliano, A. R. et al. (2019) ‘Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population’, Gynecologic Oncology. doi: 10.1016/j.ygyno.2019.03.253.
Browse journals by subject